2961 T3D2919 Benzphetamine A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) 156-08-1 5311017 C17H21N 239.167400 White powder. 129-130°C Readily soluble Oral. Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase. Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors. Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine. Half Life: 16 to 31 hours LD50: 160 mg/kg (Oral, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states. Management of acute amphetamine intoxication is largely symptomatic and includes sedation with a barbiturate. If hypertension is marked, the use of a nitrite or rapidly acting alpha receptor blocking agent should be considered. Acidification of the urine increases amphetamine excretion. (L1712) 2009-07-21T20:27:52Z 2014-12-24T20:25:53Z Benzphetamine C07538 3044 CPD-10530 Benzphetamine DB00865 true [H][C@](C)(CC1=CC=CC=C1)N(C)CC1=CC=CC=C1 C17H21N InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1 InChIKey=YXKTVDFXDRQTKV-HNNXBMFYSA-N 239.3553 239.167399677 Exogenous Solid 4.1 HMDB15003 CHEMBL1201358 4470556 <p>Dennis J. Kalota, Keith G. Tomazi, &#8220;Crystallization Method for Benzphetamine.&#8221; U.S. Patent US20080262268, issued October 23, 2008.</p>